πŸ‡ΊπŸ‡Έ FDA
Patent

US 11952427

Anti-CD40 antibodies and uses thereof

granted A61PA61P31/12A61P35/00

Quick answer

US patent 11952427 (Anti-CD40 antibodies and uses thereof) held by CytomX Therapeutics, Inc. expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CytomX Therapeutics, Inc.
Grant date
Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P31/12, A61P35/00